Dunhill Financial’s Corcept Therapeutics CORT Stock Holding History

Dunhill Financial’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$74	–	1680
2026 Q1	$74	Sell	1 -1	-50%	-$37	﹤0.01%	1509
2025 Q4	$64	Buy	+2	New	+$157	﹤0.01%	1568

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dunhill Financial's CORT Position: Q2 2026 in Review

Dunhill Financial sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 1 share — an estimated $74 sold.

Dunhill Financial first reported a position in CORT in Q4 2025 and held it in 2 quarters. The position peaked at $74 in Q1 2026. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

Dunhill Financial reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
Dunhill Financial sold 1 Corcept Therapeutics share in Q2 2026, an estimated $74.
Dunhill Financial first reported a position in Corcept Therapeutics in Q4 2025 and held it in 2 quarters.
Dunhill Financial's Corcept Therapeutics position peaked at $74 in Q1 2026.
423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Dunhill Financial's 13F filing for Q2 2026, filed 7 Aug 2026.